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Abstract
Objectives—To test the effect of bisphosphonate (BP) treatment for up to 3 years on bone
necrosis and osteocyte death in the mandible using a canine model.
Materials and Methods—Dogs were treated with clinical doses of oral alendronate (ALN, 0.2
mg/kg/day or 1.0 mg/kg/day) for 1 or 3 years. In a separate study, dogs were treated with
intravenous zoledronate (ZOL) at 0.06 mg/kg/day for 6 months. En bloc staining was used to
identify necrotic areas in the mandible; viable osteocytes were identified using lacatate
dehydrogenase.
Results—None of the treatments were associated with exposed bone, but 17–25% of dogs
treated for one year and 25–33% of dogs treated for three years with ALN showed pockets of dead
bone. Necrotic areas had no viable osteocytes and were void of patent canaliculi. No control
animals demonstrated necrotic bone. ZOL treatment for 6 months was associated with osteocyte
death greater than that seen in animals treated with ALN or saline. It is not clear whether osteocyte
death occurs because of direct toxic effects of BPs, or because suppressed remodeling fails to
renew areas that naturally undergo cell death. However, necrotic areas are associated with bone
other than the mandible, e.g., the rib, which normally undergo high rates of remodeling.
Conclusions—Reduced remodeling rate using BPs may contribute to the pathogenesis for bone
matrix necrosis. The development of an animal model that mimics important aspects of BP-related
osteonecrosis of the jaw is important to understanding the pathogenesis of osteonecrosis.
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Introduction
Osteonecrosis of the jaw (ONJ) was first identified as a serious potential health-related
problem only five years ago (1–3). Since 2005, the number of publications describing the
condition, its possible pathogenesis, prevention, treatment and the role that bisphosphonates
may or may not play in the initiation or progression of the condition have multiplied by
more than 3-fold to reach approximately 160 annually (Fig. 1). Most of these reports are
retrospective studies of the epidemiology and risk factors associated with the condition (e.g.,
see Ref 4 for one of the better reports). These reports, while useful, will never be able
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address the root causes or pathogenesis of the condition, nor allow us to study any means by
which the condition can be either prevented or treated.
In part for this reason, the American Society for Bone and Mineral Research (ASBMR) Task
Force on Bisphosphonate-Associated Osteonecrosis of the Jaw recommended as necessary
and essential “the development of an appropriate animal model” [emphasis ours] to
determine the best management approach to those with ONJ. They state, “Such an animal
model, once developed … would hopefully provide the rational/ethical basis on which
human randomized clinical trial investigations could occur.” Bisphosphonate-associated
(now termed bisphosphonate-related) osteonecrosis of the jaw (BRONJ) was defined by the
ASBMR Task Force as “an area of exposed bone in the maxillofacial region that does not
heal within 8 weeks after identification by a health care provider, in a patient who was
receiving or had been exposed to a bisphosphonate and had not had radiation therapy to the
craniofacial region (5). Thus, an animal model for BRONJ would have to be one treated
with a bisphosphonate (BP) which developed exposed bone, perhaps in response to an
infection or a dental procedure/trauma, which persisted for at least a period equivalent to the
period of time required for normal healing in that animal species. In a dog, this would be
equivalent to 4–6 weeks. No such model currently exists, and the issue of what an
appropriate model might depend in part on the role that bone remodeling plays in the
pathogenesis of BRONJ.
Clinical Relevance
Oral bisphosphonates are used to treat osteoporosis, and intravenous bisphosphonates at
high doses are used to prevent skeletal metastasis in some cancers. Bisphosphonate use
has been implicated in the pathogenesis of osteonecrosis of the jaw (BRONJ). Attempts
to recapitulate BRONJ in an animal model have the potential to improve our
understanding of the pathophysiology of BRONJ and provide a new model system to test
preventative and therapeutic approaches for this condition.
Experimental animal studies of bisphosphonates and mandibular necrosis
We have been using oral bisphosphonates in a non-ovariectomized canine model to
investigate the effect that bisphosphonates have on the mechanical and material properties of
the bone tissue. As a serendipitous part of these studies, we collected mandibles from dogs
that were treated with oral doses of alendronate (Fosamax) at doses used for the clinical
treatment of osteoporosis (on a mg/kg basis), or at 5 times that dose. Treatment with
alendronate occurred over 1, 2 or 3 years. The experimental design of this study, and data on
bone properties not related to ONJ have been reported in several publications (6–11). Data
on the changes to the mandible were reported earlier in 2008 as well (12).
En bloc basic fuchsin staining is a technique developed to identify the accumulation of
microdamage in bone and to distinguish it from artifact caused by histological processing
and sectioning (13–15). This process was also used by Frost (13) and Enlow (16) nearly 50
years ago to identify areas of bone (primarily rib) that were necrotic. Basic fuchsin works by
passively diffusing into all voids in the bone tissue matrix (blood vessels, lacunae,
canaliculi, and microcracks). Areas that do not stain lack a patent canalicular network that
would allow diffusion of the stain into the empty spaces. Therefore, large regions void of
stain can be easily identified using either standard transmission or confocal microscopy.
Areas of necrotic bone can also be assessed using enzyme histochemistry for viable
osteocytes. Our laboratory utilizes lactate dehydrogenase (LDH) to identify necrotic regions.
Living, viable osteocytes produce LDH, and will stain, whereas LDH-positive osteocytes
cannot be detected in areas of non-viable bone.
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Basic fuchsin staining was applied to cross-sections taken from various locations through
the mandibles of dogs that had been treated for one or three years with alendronate or
vehicle (n = 12/dose or group). Sections were made through the level of the 2nd premolars,
between the 3rd and 4th premolars, and through the 1st and 2nd molars (Fig. 2). These
sections were subsequently stained en bloc with basic fuchsin, and viewed with a standard
transmission microscope and with a confocal microscope. Areas devoid of stain that were at
least 500 µm2 in area were considered necrotic. Based on this, we found 25% (n = 3) of the
animals treated for three years with osteoporosis doses of alendronate, and 33% (n = 4) of
those treated with a higher dose for three years, had regions of necrotic bone (Fig. 3). Three
of the animals (n=2 treated with the lower dose and n=1 treated with the higher dose) had
two separate regions of necrosis within the same tissue section. None of the 12 animals
treated with saline vehicle for three years, demonstrated necrotic regions of bone. Those
dogs treated for only one year with the lower dose of alendronate also demonstrated a 25%
incidence of mandibular necrosis at the osteoporosis dose, and 17% (n = 2) incidence at the
higher dose (Table 1). Again, no animals in the vehicle control group demonstrated any
regions of necrotic bone in the mandible. Necrotic lesions in bisphosphonate-treated animals
were primarily restricted to the alveolar bone region, an area of rapid bone turnover under
normal conditions, although two animals treated with the higher dose of alendronate for 3
years had necrotic areas in the corpus or at the base of the mandible, where remodeling
occurs at lower rates.
It is important to stress that treatment with oral BPs, even at high doses for 3 years in these
dogs, did not create BRONJ, as defined above, in any of the dogs. Nevertheless, treatment
was associated with necrotic bone in that osteocytes in significant pockets of bone tissue
were dead. We suggest that this may be an indication of pre-ONJ that does not progress to
exposed bone unless there are other precipitating factors (eg trauma, infection, compromise
of the immune-system, or some combination of these well-defined risk factors).
Most instances of BRONJ have involved intravenous administration of zoledronate (ZOL)
or pamidronate in patients with cancer who are generally immune-suppressed, and often at
doses 10x those used to treat postmenopausal women for osteoporosis. Therefore, our
laboratory undertook a short term study in dogs to compare the effects of oral alendronate at
the osteoporosis dose (0.2 mg/kg/day) for 3 or 6 months with intravenous zoledronate given
at the dose used in cancer patients (0.06 mg/kg/month) [unpublished studies]. Sections from
the mandible were stained using LDH histochemistry and basic fuchsin to assess osteocyte
viability and matrix necrosis. In this study, no animals showed evidence of necrosis using
basic fuchsin staining. However, using LDH histochemistry there was clear evidence of
regions with non-viable osteocytes. The areas of non-viable osteocytes in the alveolar bone
were 3–4 times greater in animals treated for 6 months with i.v. ZOL compared to animals
treated either with alendronate or with saline vehicle (Fig. 4). This shows that, even short
term treatment with high doses of ZOL in a healthy dog can lead to significant osteocyte
death and necrosis of alveolar bone. Again, however, no areas of exposed bone were visible
in the oral cavity of any of these dogs.
The pathophysiology of mandibular necrosis
It is not clear whether osteocyte death subsequent to treatment with bisphosphonates in the
canine model (or in human BRONJ) occurs through direct toxic effects of bisphosphonates
on bone cells (17), or whether it occurs through reduced remodeling of regions which
normally undergo cell death (Fig. 5). Bisphosphonates, at doses consistent with those used
for osteoporosis, are known to prevent osteocyte apoptosis in vivo (18,19). There is no direct
evidence of the in vivo effects of bisphosphonates on osteocytes at higher doses, although
pamidronate and alendronate have been shown to inhibit protein prenylation in osteoblasts
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and to negatively affect osteoblast differentiation in vitro (17). Alendronate (20) and
pamidronate (21) have been shown to suppress the activity of osteoblasts in vivo, and Idris
et al. (17) recently showed that calvarial osteoblasts are capable of ingesting sufficient
amounts of alendronate in vivo to inhibit protein prenylation. Therefore, it is possible that
high doses of potent BPs delivered over a short period of time, or longer term administration
of less potent BPs, which may nevertheless have a high binding affinity (such as
alendronate) and remain in the bone for long periods of time (22), may accumulate in the
skeleton to levels that become toxic to osteocytes. The alternative hypothesis is that the
death of osteocytes and the development of some necrotic bone matrix is normal and it
accumulates with bisphosphonate treatment because remodeling is suppressed. Cell death is
a physiological process that occurs in living bone all the time. Usually dead cells are
removed by normal processes of remodeling, but in cases where remodeling is suppressed,
these cells may not be removed and may accumulate in pockets of necrotic bone. Which of
these two hypotheses is correct – if either is – remains an open question, and one that can
probably only be answered using an animal model in which necrosis can be created. In
either case, this osteocyte death without replacement inevitably leads to tissue necrosis,
which, when combined with a dental extraction or oral infection, especially in those who are
immune-compromised, could progress to frank jaw osteonecrosis.
To begin to understand whether the mechanism underlying the accumulation of necrotic
bone matrix is specific to bisphosphonates, we have assessed mandible tissue from non-
ovariectomized beagle dogs that were treated for 1 year with a different anti-remodeling
agent, the selective estrogen receptor modulator (SERM) raloxifene (Evista). These animals,
treated daily with the clinical dose of oral raloxifene, were part of the same study described
above for alendronate. To date we have assessed two different regions of the mandible in
these raloxifene-treated animals and have not identified any regions of matrix necrosis
(using basic fuchsin staining). Based on analyses of the vertebrae from these raloxifene-
treated animals compared to those treated with alendronate for 1 year, we know that the
turnover suppression is not equivalent (−20% in raloxifene and −70% in alendronate
compared to vehicle) (6,23). Therefore it remains unclear if remodeling suppression to a
similar degree as that which occurs with bisphosphonates would similarly increase the
amount of necrotic bone matrix or whether this effect (accumulation of necrotic bone) is
specific to the bisphosphonates.
The alveolar process of the mandible normally is subject to a high rate of bone turnover. The
cause for this is not known, although it may be related to the large bite forces engendered in
this region, or to the need to clear bacterial agents present in the relatively “dirty” oral
environment. Whatever the reason, it has been shown that bone turnover in the alveolar
region of the adult canine mandible is 2–4x greater than in the basal portion of the mandible
(12,24), and 15–20x higher than in bones from the appendicular skeleton (24,25). It is
possible that when this high rate of turnover is artificially suppressed with bisphosphonates,
areas which normally undergo cellular necrosis are not remodeled, but accumulate, leading
after a period of remodeling suppression to large areas devoid of viable cells. It is possible to
test whether a high rate of turnover is associated with osteocyte necrosis by comparing the
alveolar process to the basal region of the mandibular corpus (Fig. 6), a site of very low
turnover (24), and to the rib, a site of high turnover (~20%/yr, approximately half that in the
alveolar process of the mandible, but 10x higher than in other sites in the appendicular
skeleton) (25). If suppression of remodeling at sites of normally high turnover is related to
the development of large areas of cellular necrosis, then we might expect to see necrotic
bone in the rib, but not in the basal portion of the mandible, even in those samples in which
necrotic bone is found in the alveolus. In fact, this is exactly what we observe. We detected
few instances of osteocyte necrosis 500 µm2 or larger at the base of the mandible. However,
we found a 20% incidence of necrotic bone in the rib in dogs treated with alendronate at the
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osteoporosis dose, and a 40% incidence with the high dose. Thus, we hypothesize that areas
of bone that are normally subject to high rates of turnover, and in which remodeling is
artificially suppressed by as much as 85%, are subject to develop necrotic bone. Patches of
necrotic bone in non-dental tissues may never represent a serious health problem because
they are less subject to trauma in which bone is exposed, are not adjacent to epithelial
tissues, and not likely to be exposed to bacterial agents that cause infection or inflammatory
processes. It is still not clear, however, whether the regions of necrosis themselves – at
either site – are caused by a normally high rate of osteocyte death in these regions that
simply can no longer be cleared because remodeling is suppressed, or whether the rate of
vascular flow in these regions allows more bisphosphonate to enter these areas, either
permitting greater access to bone extracellular fluids around the osteocytes, or permitting
greater accumulation in the skeleton, with direct toxic consequences to the osteocytes.
If a high rate of intracortical remodeling is a necessary condition for the pathogenesis of
BRONJ, then this reflects on the future development of animal models. Mice and rats may
not provide good models for BRONJ because neither of these species, under normal
circumstances, has intracortical remodeling in the mandible. Although some have suggested
that mandibular remodeling occurs to some degree in C3H/HeJ and C57BL/6J mice, it is not
common, nor is it consistent from one mouse to another (27). The marsh rice rat (28) may
represent a potential animal model in which mandibular bone can become necrotic. Gotcher
and Jee showed that treatment with clodronate at doses between 0.1 and 10.0 mg/kg/day for
6–18 weeks led to necrotic and exposed alveolar bone, especially at the high doses and
longest period of exposure. Although rabbits have extensive intracortical remodeling in their
long bones, an examination of the adult rabbit mandible suggests that remodeling is not very
common in it either. Rabbits injected 3x/week for 8 months with 2.4 mg/kg of alendronate
or risedronate did not demonstrate any areas of necrotic tissue within the mandible upon
sacrifice. Limited osteonal remodeling was found in these rabbit mandibles (Fig. 7).
It seems that the dog, because of its ability to remodel in ways that are similar to humans,
may represent the best potential animal model for BRONJ. Demonstration of large areas of
necrotic bone in a subpopulation of dogs treated with BPs suggests the possibility that true
ONJ could develop under conditions of dental trauma or infection in these animals.
Conclusions
There is no animal model currently exists that mimics BRONJ. Treatment of dogs for 1–3
years with oral BPs, or for 6 months with i.v. zoledronate, is associated with the
development of areas of tissue necrosis and dead osteocytes in the mandible and the rib,
both sites of high bone turnover rates. It is not clear whether tissue necrosis is related to the
toxic effects of BPS at high dose, skeletal accumulation of BPs that are given for prolonged
periods of time, or whether the necrosis is simply the result of the natural process of cell
death , and that the areas are retained because suppressed remodeling prevents their
replacement. These are not questions that are likely to be answered from human clinical
studies. The development of an animal model that mimics the most important aspects of
BRONJ is vital to our understanding of the pathogenesis of this serious condition.
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Figure 1.
The number of citations in PubMed between 2003, when bisphosphonate-related
osteonecrosis was first identified, and June of 2008. Following a search using the terms
“Bisphosphonates and osteonecrosis”, citations specific to the jaw (e.g. excluding
osteonecrosis of the femoral head) were identified.
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Figure 2.
Experimental design for the initial experiments treating dogs for 3 years with two different
doses of oral alendronate. The lower dose is the dose used to treat postmenopausal women
with osteoporosis; the higher dose is used to treat Paget’s disease. Dogs were 1–2 years old
at the initiation of treatment. Calcein labeling was initiated 3 weeks prior to sacrifice.
Sections were taken at four locations through the mandible.
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Figure 3.
Photomicrographs of mandible bone matrix necrosis in beagle dogs treated with
bisphosphonate. Following 1 or 3 years of oral alendronate treatment, mandibles were
stained en bloc with basic fucshin which allows identification of necrotic bone matrix due to
its lack of stain uptake compared to viable regions of bone. Images are from three different
animals treated with oral alendronate for 1 or 3 years.
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Figure 4.
Accumulation of regions with non-viable osteocytes in the mandible is prominent with high
dose zoledronate treatment. Following 6 months of treatment with either saline (VEH), oral
alendronate (ALN), or intravenous zoledronate (ZOL) mandible tissue was assessed for
osteocyte viability using lactate dehydrogenase staining, which results in viable cells
staining blue. Using an ordinal scale classification, it can be shown that regions of non-
viable osteocytes were more prominent in ZOL-treated animals (panel A). Although both
VEH and ALN-treated animals had regions of non-viable osteocytes, there tended to be very
few regions, and these were small (panel B). Conversely, some of the regions of non-viable
osteocytes in ZOL-treated animals were significant in size (panel C).
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Figure 5.
Flow chart showing two possible pathways for the accumulation of necrotic bone with non-
viable osteocytes. In one situation (left side), bisphosphonates accumulate in the skeletal
tissue to levels that become toxic to osteocytes, causing their death, and subsequent matrix
necrosis. A second pathway (right side) is through reduced remodeling caused by
bisphosphonates which would inhibit the repair of osteocytes that die as a consequence of
normal physiological processes associated with tissue renewal. Failure to replace the dead
osteocytes would then lead to larger regions of necrosis without viable osteocytes.
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Figure 6.
Photomicrographs of mandible cross-sections from animals treated for 3 years with vehicle
(VEH) or alendronate (ALN). Through administration of fluorochrome labels at the end of
the experiment, the level of bone remodeling can be determined using ultraviolet fluorescent
microscopy. Based on the number of calcein-labeled osteons it is clear that there is a high
level of turnover in VEH animals, particularly in the alveolar portion of the bone.
Conversely, far fewer osteons are labeled in the ALN-treated animal, indicative of a reduced
remodeling rate.
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Figure 7.
Photomicrographs of alveolar bone in a two year old beagle dog (panels A and B) and a one
year old rabbit (panels C and D). The difference in osteon density, illustrated using
brightfield microscopy of basic fuchsin stained sections (A&C), clearly illustrates the lower
rate of secondary osteonal remodeling in the rabbit mandible. This can also be appreciated
using polarized light (B and D), which shows the rabbit mandible alveolar process is
unremodeled primary bone even in this mature animal. If bisphosphonate-related
osteonecrosis of the jaw (BRONJ) is found more often in regions of bone that have high
basal remodeling rates, then rabbits are not likely to be a very good animal model for the
pathogenesis of BRONJ.
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Table 1
Mandible necrosis summary
1 year treatment
Treatment
Dose
(mg/kg/day)
Animals Sites per
animal
Animals w/
Necrosis
Vehicle 12 1 0
Alendronate 0.2
1.0
12
12
3
3
3 (25%)
2 (17%)
Raloxifene 0.5 12 1 0
3 year treatment
Treatment
Dose
(mg/kg/day)
Animals Sites per
animal
Animals w/
Necrosis
Vehicle 12 4 0
Alendronate 0.2
1.0
12
12
4
4
3 (25%)
4 (33%)
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